home / stock / drmaw / drmaw message board
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Dermata Therapeutics Inc. Warrant Company Name:
DRMAW Stock Symbol:
NASDAQ Market:
Dermata Therapeutics Inc. Warrant Website:
SAN DIEGO, CA / ACCESSWIRE / May 17, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today announced the entry into definitive agreement...
- DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial enrollment remains on track - - Dermata continues discussions with potential botulinum toxin partners for DMT410 - - Received issuance of Japanese patent for DMT410 for the treatment of hyperhidrosis - SAN...
- This is the Company's first patent issued for DMT410, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis - - The Company is currently discussing partnership opportunities to advance development of DMT410 - - In 2022, the Japanese prevalence of hyperhid...